Japan Drive Prostate Cancer Treatment Market at 7.8% CAGR on Radioligand & Precision Oncology Advances

Leander, Texas and Tokyo, Japan - Jan.08.2026
As per DataM Intelligence research report "Prostate Cancer Treatment Market size reached US$ 13.22 billion in 2024 and is expected to reach US$ 28.10 billion by 2033, growing at a CAGR of 7.8% from 2025 to 2033." Rising incidence of prostate cancer in aging populations, advancements in diagnostic technologies enabling early detection, expanding indications for novel therapies like radioligand and targeted treatments, and increasing demand for precision oncology are fueling growth in the prostate cancer treatment market.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/prostate-cancer-treatment-market?sindhuri

Japan: Recent Industry Developments
✅ In November 2025, Retrospective studies highlighted shifts toward androgen receptor signaling inhibitors (ARSIs) in metastatic castration-sensitive prostate cancer (mCSPC) treatment patterns in Japan since 2020.
✅ In October 2025, Curium Group, PeptiDream, and PDRadiopharma enrolled the first patient in a Phase 2 trial for 64Cu-PSMA-I&T, a PET radiopharmaceutical for imaging high-risk prostate cancer.
✅ In 2025, Investments expanded in proton therapy centers with advanced technology like Varian's ProBeam, improving access to targeted prostate cancer treatments.

United States: Recent Industry Developments
✅ In March 2025, Novartis received FDA approval for Pluvicto (177Lu-PSMA-617), expanding its use to delay chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer patients.
✅ In 2025, Positive data from trials like LUNAR supported radioligand therapies, delaying hormone therapy needs and improving outcomes in recurrent cases.
✅ In 2025, Advancements in combination therapies, including niraparib with abiraterone and triplet regimens, demonstrated significant delays in disease progression for high-risk patients.

Prostate Cancer Treatment Market: Drivers
The prostate cancer treatment market is driven by the rising global prevalence of prostate cancer (1.57 million new cases in 2024, projected to 1.80 million by 2030), aging demographics, improved screening and diagnostics, and innovations in therapies including radioligand, hormone, targeted, and immunotherapies. Demand for treatments offering better survival rates, reduced side effects, and management of advanced stages like mCRPC fuels investment in novel therapeutics. Supportive regulatory approvals, precision medicine approaches targeting PSMA and genetic mutations, and focus on long-term care further accelerate market momentum.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/prostate-cancer-treatment-market?sindhuri

Prostate Cancer Treatment Market: Major Players
Astellas Pharma, AstraZeneca, Bayer AG, Dendreon Pharmaceuticals, Exelixis Inc., Ferring B.V., Johnson & Johnson (via Janssen Pharmaceuticals), Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis, Tolmar, Inc.

Segment Covered in the Prostate Cancer Treatment Market:
By Stage
Stage I, Stage II, Stage III, Stage IV.
By Therapy Type
Radioligand Therapy, Radiation Therapy, Chemotherapy, Hormone therapy, Targeted therapy, Immunotherapy, Surgery.

Regional Analysis
North America - Dominant Share
North America leads with the highest market share due to high prevalence, advanced healthcare infrastructure, early adoption of innovative therapies, robust R&D, leading pharmaceutical presence, and favorable regulatory frameworks like FDA approvals.
Asia Pacific - Fastest-Growing
Asia Pacific expands rapidly with rising incidence, aging populations, improving diagnostics and access, government investments, and increasing adoption of advanced treatments.
Europe - Significant Share
Europe holds a significant share with the highest incidence rates and emphasis on early detection and comprehensive care.
South America - Gradual Growth
South America shows steady progress driven by growing awareness and healthcare improvements.
Middle East & Africa - Emerging Growth
Middle East & Africa rises with investments in oncology infrastructure and rising disease burden.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=prostate-cancer-treatment-market&sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.